BIO-key Receives Notice of Non-Compliance from Nasdaq Related to Delay of its Form 10-Q Filing
BIO-key Receives Notice of Non-Compliance from Nasdaq Related to Delay of its Form 10-Q Filing
BIO-key (OTC Markets: BKYI) received a Nasdaq notice of non-compliance with Listing Rule 5250(c)(1) because it did not timely file its Form 10-Q for the quarter ended March 31, 2026.
BIO-key (OTC Markets: BKYI) received a Nasdaq notice of non-compliance with Listing Rule 5250(c)(1) because it did not timely file its Form 10-Q for the quarter ended March 31, 2026.
A Nasdaq Hearing Panel will consider this issue when deciding BIO-key’s continued listing on the Nasdaq Capital Market.
Loading...
Loading translation...
Positive
None.
Negative
Non-compliance with Nasdaq Listing Rule 5250(c)(1) for late Form 10-Q filing
Nasdaq Hearing Panel to weigh non-compliance in continued listing determination
On Jun 11, the first trading day after this news, BKYI closed 2.81% below the previous close.
Data tracked by StockTitan Argus for the Jun 11 session.
Market Context
This announcement details that Nasdaq deemed BKYI non-compliant with Listing Rule 5250(c)(1) because...
Analysis
This announcement details that Nasdaq deemed BKYI non-compliant with Listing Rule 5250(c)(1) because the company did not timely file its Form 10-Q for the period ended March 31, 2026. The Nasdaq Hearing Panel will consider this in deciding on BKYI’s listing status. In recent months, the company has paired stronger revenue trends and improving losses with repeat filing delays and prior Nasdaq actions. Investors may watch future SEC filings and Nasdaq communications to evaluate how governance and reporting risks evolve.
Disclosed Nasdaq trading suspension and OTC move while reiterating growth and profit targets.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
form 10-q, nasdaq listing rule 5250(c)(1), securities and exchange commission, nasdaq capital market, +2 more
6 terms
form 10-qregulatory
"failure to timely file its Quarterly Report on Form 10-Q for the period"
A Form 10-Q is a detailed report that publicly traded companies are required to file with regulators three times a year, providing an update on their financial health and business activities. It is important for investors because it offers timely insights into a company's performance, helping them make informed decisions about buying or selling stocks. Think of it as a regular check-up report that shows how well a company is doing.
nasdaq listing rule 5250(c)(1)regulatory
"not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed"
Nasdaq Listing Rule 5250(c)(1) requires companies listed on the Nasdaq stock exchange to promptly notify the exchange if their stock price falls below a certain minimum level, known as the "initial listing standards." This rule helps ensure that investors are aware of significant declines in a company's stock value, which could signal financial trouble or increased risk. Essentially, it helps maintain transparency and protect investors by keeping them informed about important changes in a company's stock performance.
securities and exchange commissionregulatory
"file all required periodic financial reports with the Securities and Exchange Commission"
A national government agency that enforces rules for buying, selling and disclosing information about stocks and other investments, acting like a referee and scorekeeper for financial markets. It requires companies to share clear, regular financial and business information and investigates fraud or rule-breaking, which matters to investors because those rules and disclosures help ensure fair prices, reduce hidden risks and make it easier to compare investment choices.
nasdaq capital marketregulatory
"regarding the Company’s continued listing on the Nasdaq Capital Market."
The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.
identity and access managementtechnical
"a global leader in Identity and Access Management (IAM) and biometric"
Identity and access management is the set of tools and processes that verify who a person or device is and control what digital resources they can use, like a company’s system for issuing security badges and setting which doors each badge opens. It matters to investors because strong identity controls reduce the chance of costly data breaches, regulatory fines and downtime, protect customer trust, and can lower IT costs and operational risk.
biometric authenticationtechnical
"Identity and Access Management (IAM) and biometric authentication technologies,"
Biometric authentication uses a person’s unique physical or behavioral traits—such as fingerprints, facial features, iris patterns, or voice—to verify identity instead of passwords or codes. For investors, it matters because faster, more secure login methods can boost customer trust and reduce fraud-related costs, while also creating opportunities and risks around technology adoption, data privacy rules, and the companies that build or supply the biometric systems.
HOLMDEL, N.J., June 10, 2026 (GLOBE NEWSWIRE) -- BIO-key International, Inc. (OTC Markets: BKYI), a global leader in Identity and Access Management (IAM) and biometric authentication technologies, announced today that it has received a notification letter from The Nasdaq Stock Market, LLC informing the Company that it was not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission, due to the Company’s failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026. In the notice, Nasdaq further informed the Company that the Nasdaq Hearing Panel will consider the forgoing in rendering a determination regarding the Company’s continued listing on the Nasdaq Capital Market.
About BIO-key International, Inc. (www.BIO-key.com) BIO-key is revolutionizing authentication and cybersecurity with biometric-centric, multi-factor identity and access management (IAM) software securing access for over forty million users. BIO-key allows customers to choose the right authentication factors for diverse use cases, including phoneless, tokenless, and passwordless biometric options. Its cloud hosted or on-premise PortalGuard IAM solution provides cost-effective, easy-to-deploy, convenient, and secure access to computers, information, applications, and high-value transactions.
Investor Contacts: William Jones, David Collins Catalyst IR BKYI@catalyst-ir.com 212-924-9800
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Why did BIO-key (BKYI) receive a Nasdaq non-compliance notice on June 10, 2026?
BIO-key received a Nasdaq non-compliance notice because it failed to timely file its Form 10-Q for the quarter ended March 31, 2026. According to the company, this delay triggered non-compliance with Nasdaq Listing Rule 5250(c)(1).
What is Nasdaq Listing Rule 5250(c)(1) and how does it affect BIO-key (BKYI)?
Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file required periodic financial reports with the SEC. BIO-key’s late Form 10-Q filing led Nasdaq to deem the company non-compliant, which may influence decisions about its continued listing status.
How does BIO-key’s delayed Form 10-Q for March 31, 2026 impact its Nasdaq listing?
BIO-key’s delayed Form 10-Q filing caused a Nasdaq non-compliance notice, and a Hearing Panel will consider this in deciding the stock’s continued listing. According to the company, this review directly links the filing delay to potential listing outcomes.
What period does the late BIO-key (BKYI) Form 10-Q cover in the Nasdaq notice?
The late BIO-key Form 10-Q covers the quarter ended March 31, 2026. According to the company, failure to timely file this specific quarterly report prompted Nasdaq’s non-compliance notification under Listing Rule 5250(c)(1).
What role will the Nasdaq Hearing Panel play in BIO-key’s (BKYI) listing status?
The Nasdaq Hearing Panel will consider BIO-key’s non-compliance from the late Form 10-Q when determining its continued listing on the Nasdaq Capital Market. According to the company, this panel’s review is a key step in the listing decision process.
